Vemurafenib showed promising activity against several nonmelanoma cancers carrying BRAF V600 mutations in a preliminary phase II study reported online Aug. 20 in the New England Journal of Medicine....

Field of Interest: Oncology

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.